LEXARIA BIOSCIENCE CORP. Amortization
LEXARIA BIOSCIENCE CORP. (LEXX) reported Amortization of -$39.93 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. amortization for the quarter ending 2026-05-31 was -$13.91K.
- LEXARIA BIOSCIENCE CORP. amortization for the quarter ending 2026-02-28 was -$14.01K.
- LEXARIA BIOSCIENCE CORP. amortization for the quarter ending 2025-11-30 was -$12.01K.
- LEXARIA BIOSCIENCE CORP. amortization for the quarter ending 2025-08-31 was -$12.01K.
- LEXARIA BIOSCIENCE CORP. amortization for fiscal 2024 was -$42.45K, a 1012.66% decline from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. amortization for fiscal 2023 was $4.65K, a 27.25% increase from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. amortization for fiscal 2022 was $3.65K, a 66.55% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. amortization for fiscal 2021 was $10.93K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month | Amortization 12 month | Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | -$13.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | -$27.92K derived: sum of 2 quarters · filed 2026-07-13 | -$39.93K 10-Q · filed 2026-07-13 | -$51.94K derived: sum of 4 quarters · filed 2026-07-13 | |
| 2026-02-28 | -$14.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | -$26.01K 10-Q · filed 2026-04-13 | -$38.02K derived: sum of 3 quarters · filed 2026-07-13 | -$59.77K derived: sum of 4 quarters · filed 2026-07-13 | |
| 2025-11-30 | -$12.01K 10-Q · filed 2026-01-13 | -$24.02K derived: sum of 2 quarters · filed 2026-07-13 | -$45.77K derived: sum of 3 quarters · filed 2026-07-13 | ||
| 2025-08-31 | -$12.01K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-13 | -$33.76K derived: sum of 2 quarters · filed 2026-07-13 | -$51.23K 10-Q · filed 2026-07-13 | ||
| 2025-05-31 | -$21.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | -$39.22K 10-Q · filed 2025-07-14 | |||
| 2025-02-28 | -$17.46K 10-Q · filed 2025-04-14 | ||||
| 2024-08-31 | -$42.45K 10-K · filed 2025-11-28 | $0.00 10-K · filed 2024-11-26 | |||
| 2023-11-30 | -$8.27K 10-Q · filed 2024-01-12 | -$63.21K derived: sum of 2 quarters · filed 2024-01-12 | -$61.45K derived: sum of 3 quarters · filed 2024-01-12 | -$61.00K derived: sum of 4 quarters · filed 2024-01-12 | |
| 2023-08-31 | -$54.94K 10-Q · filed 2024-01-12 | -$53.17K derived: sum of 2 quarters · filed 2024-01-12 | -$52.73K derived: sum of 3 quarters · filed 2024-01-12 | $4.65K 10-K · filed 2024-11-26 | |
| 2023-05-31 | $1.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | $2.21K derived: sum of 2 quarters · filed 2023-07-14 | $4.65K 10-Q · filed 2023-07-14 | $6.96K derived: sum of 4 quarters · filed 2023-11-20 | |
| 2023-02-28 | $445.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-04-14 | $2.88K 10-Q · filed 2023-04-14 | $5.20K derived: sum of 3 quarters · filed 2023-11-20 | ||
| 2022-11-30 | $2.44K 10-Q/A · filed 2023-01-18 | $4.75K derived: sum of 2 quarters · filed 2023-11-20 | |||
| 2022-08-31 | $2.32K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $3.65K 10-K · filed 2023-11-20 | |||
| 2022-05-31 | $1.34K 10-Q · filed 2022-07-14 | ||||
| 2021-08-31 | $1.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $10.93K 10-K · filed 2022-11-28 | |||
| 2021-05-31 | $9.32K 10-Q · filed 2022-07-14 | ||||
| 2015-11-30 | $155.00 10-Q · filed 2016-01-08 | ||||
| 2014-11-30 | $0.00 10-Q · filed 2016-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |